Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Shree Ganesh Remedies Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹647.80 |
|---|---|
| Day's Range | ₹637.15 - ₹655.00 |
| Open | ₹645.00 |
| 52 Week Range | ₹381.10 - ₹665.00 |
| Volume | 952 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 6.17 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 46.85 |
| TTM EPS (₹) | 13.83 |
| P/E Ratio | 39.58 |
| Book Value(₹) | 5.11 |
| PAT Margin (%) | 20.71 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 19.53 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1085.96 | 244.32 |
| Expenses | N/A | N/A |
| PBT | 312.97 | 87.81 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 230.98 | 65.97 |
About Shree Ganesh Remedies Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Chandulal Manubhai Kothia |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,29,145.05 | 1,792.70 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,72,988.62 | 6,737.70 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,322.13 | 4,457.40 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,20,125.61 | 8,423.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,12,149.13 | 1,390.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,09,422.92 | 1,108.50 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,06,482.91 | 1,284.30 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,02,996.20 | 2,258.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 97,913.19 | 1,005.15 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,382.57 | 2,373.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Shree Ganesh Remedies informs about outcome of board meeting
Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Shree Ganesh Remedies has informed that the Board of Directors of the Company at its meeting held on today, Thursday, May 14, 2026 have considered and approved following: 1. Audited Financial Results (Standalone and Consolidated) of the company for the quarter and the financial year ended on March 31, 2026, along with the reports of Auditors thereon pursuant to Regulation 33 of SEBI LODR Regulations. Copy of the said Financial Results (Standalone and Consolidated) and Auditors Report is enclosed. Pursuant to Regulation 33 of SEBI LODR Regulations, it has declared that the statutory auditors have issued (Standalone and Consolidated) Audit Reports with unmodified opinion on the financial results of the Company for the year ended March 31, 2026; 2. Re-appointment of S N D K & Associates LLP, Chartered Accountants (Firm Registration No: W100060) as an Internal Auditors of the Company for the FY 2026-27. Details as required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762 /2026 dated January 30, 2026 are given as Annexure ‘A’. The Board of Directors Meeting commenced at 03:30 pm and concluded at 04:10 pm.
Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed the Notice convening the 21st Annual General Meeting (‘AGM’) of shareholders of the Company, scheduled to be held on Thursday, July 2, 2026 at 3.00 pm (IST) through Video Conferencing (‘VC’)/ through Other Audio-Visual Means (‘OAVM’). The Notice of 21st AGM is also available on the Company’s website at www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Viyash Scientific informs about acquisition
Lupin informs about press release
GlaxoSmithKline Pharmaceuticals informs about letter for weblink for annual report
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Shree Ganesh Remedies Ltd. is ₹647.80 as of 2026-06-09.
The market capitalisation of Shree Ganesh Remedies Ltd. is ₹832.07 as of 2026-06-08.
The 1-year return of Shree Ganesh Remedies Ltd. is 28.15% as of 2025-06-06.
The P/E ratio of Shree Ganesh Remedies Ltd. is 39.58 as of 2026-06-09.
The 52-week high and low of Shree Ganesh Remedies Ltd. are ₹665.00 and ₹381.10, respectively, as of 2026-06-09.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
